GSK-J4, a JMJD3 inhibitor, was recently shown to inhibit glioma cell growth in association with elevation of H3K27me3 154, and targeting KDM4A reduced glioma cell survival via increased autophagy 155. The gene discussed is KDM6B; the disease is central nervous system cancer.